Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 26.72M P/E - EPS this Y 22.80% Ern Qtrly Grth -
Income -25.65M Forward P/E -1.00 EPS next Y 32.00% 50D Avg Chg -25.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -54.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -75.00%
Recommedations 2.00 Quick Ratio 0.07 Shares Outstanding 10.56M 52W Low Chg 9.00%
Insider Own 26.87% ROA -118.07% Shares Float 6.45M Beta -
Inst Own 3.64% ROE - Shares Shorted/Prior 486.17K/424.54K Price 0.38
Gross Margin - Profit Margin - Avg. Volume 387,188 Target Price 35.00
Oper. Margin - Earnings Date Aug 12 Volume 225,391 Change -4.83%
About NRX Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

NRX Pharmaceuticals, Inc. News
05/14/24 NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update
05/08/24 NRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone Update
05/08/24 NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024
05/07/24 NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024
05/06/24 NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression
04/30/24 NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression
07:32 AM NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement
07:30 AM NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock
04/17/24 NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock
04/17/24 NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections
04/15/24 NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
04/08/24 NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
04/01/24 NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
03/28/24 NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights
03/28/24 NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
03/26/24 UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
03/25/24 NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK
03/21/24 NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024
03/21/24 NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholders
07:30 AM NRx Pharmaceuticals (NASDAQ:NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholders
NRXP Chatroom

User Image DavidBG Posted - 5 hours ago

$NRXP As the naked shorts attempt to cover before the dividend finally happens, they will be continually tightening their own noose. Every time they buy a share to cover, that share ceases to exist, because there was no underlying share in the first place. As the supply of shares dwindles, shares available to borrow will become even harder to find, and the cost to borrow will skyrocket even more.

User Image Billyharr Posted - 8 hours ago

$NRXP where did the bashers go? Disappeared???

User Image CHARTECH Posted - 20 hours ago

$NRXP I believe company has 3 great shots. 1. NRX-101 for akathisia. Received first milestone of $5m already from partners Alvogen and Lotus. “The second portion of the milestone will be $4 million and, as before, be triggered by a positive response to the Company's planned end of phase 2 meeting with FDA.”

User Image Moneytlxbswlks Posted - 23 hours ago

$NRXP Does anyone here remember DonnieK? I used to hate what he pushed.

User Image Moneytlxbswlks Posted - 23 hours ago

$NRXP I bought into this stock a few years back because Dr. JJ knows his stuff and it's a GRAND SLAM. I do question the Georgia thing that came to nothing, all the other promises he made to us. The lawsuits that were dismissed on their behalf. I am just being honest and down over 50K on this. The wife isn't happy and don't care if it goes to zero so I can write it off for the next 15. I'm still holding solid because you only lose when you sell. Only trust real performance is all I can advise because this company hasn't done this for years. Don't get sucked into their lies. I guess I could day trade this with more money, lol. Better things to do and frustrating. We shall see.

User Image webberj1 Posted - 23 hours ago

$NRXP Have a good weekend javittards!

User Image surfsup11 Posted - 1 day ago

$NRXP all depression meds including soc have black label box warning for increased suicidality. You do the math

User Image Trubach Posted - 1 day ago

$NRXP those companies with huge debt are getting pumped 1000s percent but we cant even break $4. Joke

User Image Trubach Posted - 1 day ago

$NRXP more sellers today than buyers

User Image BigDicBandit Posted - 1 day ago

$NRXP not bad for a Friday almost the same as last Friday lfg next week 5$

User Image jzhuu Posted - 1 day ago

$NRXP Some retards sold nrxp at $3.07 in the early morning.

User Image BlazingStocks Posted - 1 day ago

$NRXP - Company plans to file a New Drug Application (NDA) for Accelerated Approval under Breakthrough Therapy and Priority Review of NRX-101 in treatment of bipolar depression in people at risk of akathisia, based on the Phase 2b/3 and STABIL-B data https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-reports-200100617.html

User Image jzhuu Posted - 1 day ago

$NRXP I really wish those pump and dump guys made some money, but then suddenly missed the opportunity when the price jumped.

User Image jonny80s Posted - 1 day ago

$NRXP almost identical pump and dump as yesterday…. Only 1/10 the volume.

User Image BlazingStocks Posted - 1 day ago

$NRXP - 2024 Catalysts: Positive Clinical Data, Two Planned NDAs, Company Launch of Hope Therapeutics; FDA QIDP award in cUTI and New Schizophrenia Opportunity https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-reports-200100617.html

User Image ddimlich Posted - 1 day ago

$NRXP SP is all about supply and demand. Shorts have no more ammo or the ammo is very expensive. Longs are not going anywhere. Most day traders are out of the play. It’s simple don’t let MM stop loss raid your shares. HODL until revenue, HOPE spinoff, FDA comments lead to Alvogen and Lotus 2nd payment. That will put us well over 25 per share or 2.50 pre split. Maybe that is lower than your average, but if that happens then one can assume it gets over 50 soon enough with room to grow.

User Image BlazingStocks Posted - 1 day ago

$NRXP News May 14, 2024 NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-reports-200100617.html

User Image jzhuu Posted - 1 day ago

$NRXP Any price below $10 is a huge discount.

User Image BigJohn57 Posted - 1 day ago

$NRXP Rally cap on!

User Image Trubach Posted - 1 day ago

$NRXP can we see $4+ today?

User Image alwaysWinVlmr Posted - 1 day ago

$NRXP borrow fee is over 100% for 7 calendar days. Do you like that Sabby @RRKD2053?

User Image jonny80s Posted - 1 day ago

$NRXP any chance this will break through $4 tomorrow? I’ld prefer to be in the $10+ range.

User Image BlazingStocks Posted - 2 days ago

$NRXP News May 08, 2024 NRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone Update https://finance.yahoo.com/news/nrx-pharmaceuticals-eyes-first-commercial-135500896.html

User Image Trubach Posted - 2 days ago

$NRXP to much manipulation today

User Image pdwpdw Posted - 2 days ago

$NRXP Below is a near in look at my technical chart (Click on chart to enlarge). There are two triggered and still valid inverse head and shoulders on the chart (see the right shoulders of each formation along the red and orange necklines) There is a new possible inverse head and shoulder forming over the last few days (see blue neckline), projecting to around $5.40. It would be great if it triggered today by a close over the blue neckline, and even better if today's close was over the 200 day moving average at $3.70, making that moving average and the old $3.60 gap price (3 times tested from below over the last two weeks) some support for price not falling back below the blue neckline.

User Image rongoldburger Posted - 2 days ago

$NRXP …are you high⁉️ 🤭

User Image Trubach Posted - 2 days ago

$NRXP Shorts are so desperate and playing with fire. Cant wait to see GME and AMC action here soon. I think its coming

User Image Trubach Posted - 2 days ago

$NRXP wow, this guy has many followers and he has no idea this stock had 10:1 RS. So he called NRXP at .46 presplit and now stock is at 3.70 which is .37 presplit. Have no idea how he got that many followers

User Image ddimlich Posted - 2 days ago

$NRXP time for after lunch run.

User Image sillyboi2233 Posted - 2 days ago

$NRXP I mean, this should be at least a $20 stock.

Analyst Ratings
HC Wainwright & Co. Buy May 25, 23
HC Wainwright & Co. Buy Feb 2, 23
Ascendiant Capital Buy Nov 9, 22
HC Wainwright & Co. Buy Jun 30, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Gorovitz Aaron Director Director Aug 30 Buy 0.3199 35,000 11,196 105,000 09/11/23
Hurvitz Chaim Director Director Aug 30 Buy 0.2875 70,000 20,125 570,000 09/11/23
Javitt Jonathan C Chief Scientist Chief Scientist Aug 23 Buy 0.33 100,000 33,000 446,332 08/24/23
Javitt Jonathan C Chief Scientist Chief Scientist Aug 22 Buy 0.322 200,000 64,400 346,332 08/23/23
Willard Stephen H CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Dec 16 Buy 1.17 50,000 58,500 50,000 12/19/22
VAN VOORHEES SETH CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER Dec 16 Buy 1.10 30,000 33,000 46,337 12/19/22
VAN VOORHEES SETH CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER Nov 25 Buy 1.11 16,337 18,134 16,337 12/19/22
Javitt Daniel C. 10% Owner 10% Owner Nov 29 Sell 1.5 22,171 33,256 9,634,793 12/01/22
Flynn Patrick John Director Director Nov 28 Buy 1.25 11,750 14,688 1,750 11/29/22
VAN VOORHEES SETH CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER Nov 25 Buy 1.11 16,337 18,134 16,377 11/28/22
Javitt Daniel C. 10% Owner 10% Owner Nov 16 Sell 1.04 166,737 173,406 9,656,964 11/18/22
Javitt Daniel C. 10% Owner 10% Owner Nov 11 Sell 1.0063 49,200 49,510 9,823,701 11/15/22
Javitt Daniel C. 10% Owner 10% Owner Jul 29 Sell 1.0094 784,063 791,433 9,872,901 08/02/22
Javitt Daniel C. 10% Owner 10% Owner Jun 03 Sell 0.67 445,712 298,627 12,656,964 06/07/22
Javitt Jonathan C Chief Scientist Chief Scientist Jun 01 Buy 58.00 100,000 5,800,000 146,332 06/02/22